← All publications

Academic research

ANR / EP PerMed: CGT4PM2027 call on cell and gene therapy

Fund transnational research projects that develop and validate innovative cell and gene therapies in personalised medicine.

Status
Open
Next deadline
20 January 2027 at 14:00 (pre-proposals); 25 May 2027 at 14:00 (full proposals)
Operator
ANR / EP PerMed

At a glance

Programme
Horizon Europe: EP PerMed partnership, JTC2027 joint transnational call (CGT4PM2027)
Territory
24 countries and 10 European regions, 37 funding organisations; the ANR funds the French partners
Beneficiaries
Consortia of at least three partners from three participating countries: academic research, clinical and public health sector, companies and private non-profit organisations
Type of aid
Research project funding, on actual costs under the ANR financial regulations
Amount / rate
ANR: up to €330,000 for a coordinator, €280,000 for a partner, at least €15,000; call budget above €38 million
Availability
Open since 16 November 2026; two stages, pre-proposals by 20 January 2027 at 14:00, full proposals by 25 May 2027 at 14:00

Information up to date as of 17 November 2026, valid until 20 January 2027. Scheme conditions change: check with the funding body or ask us for confirmation.

The European Partnership for Personalised Medicine, EP PerMed, supported by the European Union under Horizon Europe, opened its joint transnational call JTC2027 (CGT4PM2027) on 16 November 2026. The call is dedicated to cell and gene therapies for personalised medicine. It brings together 37 funding organisations, with a budget of more than €38 million. The ANR (French National Research Agency) funds the French partners, up to €330,000 for a coordinator. Submission takes place in two stages: pre-proposals by 20 January 2027, full proposals by 25 May 2027.

Which projects are funded?

The call funds transnational research projects in human health on cell and gene therapies for personalised medicine. Projects must develop and validate an innovative therapy of this kind. They use at least one of the following approaches:

  • somatic cell therapy;
  • gene therapy: substitution, addition, suppression or genome editing;
  • combined cell and gene therapy;
  • novel biological products, such as mRNA or extracellular vesicles.

All disease areas are encouraged. Clinical trials (phases I to IV) are excluded; the call text gives the full list of exclusions.

Who can apply?

Consortia. Only transnational projects are funded:

  • at least three partners from three different countries (EU Member States or associated countries) whose funders take part in the call, each eligible and requesting funding from its funder, and independent of each other;
  • at most six partners at the pre-proposal stage, seven if the consortium includes a third partner from the same country (provided it applies to at least two different funders in that country);
  • at most two partners per funder;
  • at least one early-career researcher as principal investigator of a partner;
  • at most one partner on own funds, in a consortium of at least four partners.

At the full proposal stage, one more partner can be added if it comes from an underrepresented country or region, according to a list sent to the invited coordinators.

Partners. Three categories can take part, according to each funder's rules:

  • academia: teams from universities, other higher education institutions and research institutes;
  • the clinical and public health sector: teams from hospitals and other healthcare institutions;
  • private for-profit partners, such as SMEs, and non-profit partners, such as foundations and associations.

The call text strongly encourages consortia that combine these three categories.

French partners. The ANR funds only French partners, that is, those with at least one establishment in France that request its funding. Private partners give their SIRET number from the pre-proposal onwards. The coordinator must be eligible for funding from their own funder, and cannot change between the two stages.

Which costs are eligible?

For partners funded by the ANR, only eligible costs are covered, under the ANR financial regulations for actual-cost funding and its fact sheet on eligible costs. The funding rate depends on the type of partner and the type of costs: the financial regulations set it out.

How much funding is available?

  • ANR funding: up to €330,000 for a coordinating partner, up to €280,000 for a partner.
  • No funding below €15,000.
  • Project duration: 36 months at most.
  • Total call budget: more than €38 million, shared among 37 funding organisations from 24 countries and 10 European regions.

Partners from other countries are funded by their own organisation, under its rules.

Main selection criteria

Pre-proposals and then full proposals are assessed by at least three independent experts, on three equally weighted criteria, each scored out of 5:

  • excellence: clarity of the objectives and fit with the call, ambition beyond the state of the art, soundness of the method and of the multidisciplinary approach, consideration of sex and gender and of underrepresented populations, open science practices and patient involvement;
  • impact: credibility of the pathway to the expected results, scale of the contributions, potential for translation into personalised medicine (with a work package dedicated to quality specifications and preclinical regulatory requirements), dissemination and exploitation plan, added value of the transnational collaboration;
  • quality and efficiency of the implementation.

A score of at least 3 out of 5 is required on each criterion and 9 out of 15 in total. Projects are then ranked, and funded according to this ranking and the funders' budgets.

Points to watch

  • Scientific submission is made on the EP PerMed PT-Outline platform, in English. At stage 2, partners requesting ANR funding also register on the ANR IRIS platform.
  • Clinical trials are not funded.
  • A project cannot be similar to another proposal under evaluation or already funded by the ANR.
  • Partners from countries under European Union sanctions (notably Russia and Belarus) are excluded, and make the ANR partners associated with them ineligible.
  • Israel's participation still depends on a decision by its funder.
  • Do not confuse this call with the EP PerMed 2026 calls, which are separate.

The CHOICE view

The call is aimed at teams with an innovative cell or gene therapy that they want to take to the threshold of the clinic, in a European consortium. The timetable is short: a consortium from at least three countries, with an early-career researcher among the principal investigators, must be in place by 20 January. A French company can be funded by the ANR, which opens the door to biotechs that want to combine their product with academic and clinical teams. CHOICE supports the search for partners, the pre-proposal and the budget of the French partners.

How to prepare your project

  • Check that the therapy fits one of the call's approaches and that no clinical trial is planned.
  • Build the consortium: at least three participating countries, at most two partners per funder, an early-career researcher, and if possible academic, clinical and private teams. The EP PerMed partnering tool can help.
  • Check the rules of each foreign partner's funder in the guidelines for applicants.
  • For each French partner, cost the budget within the ANR ceilings (€330,000 or €280,000) and prepare the SIRET number of private partners.
  • Submit the pre-proposal on PT-Outline before 20 January 2027 at 14:00.

Official sources

The conditions of a scheme can change. This fact sheet was checked on the date shown; only the call specifications, the official texts and the funding body's decision are authoritative.

How CHOICE works on this kind of application

Finding the right scheme is only one step. What matters happens before: clarifying the project, gathering the expected evidence, bringing in the right partners and sequencing commitments.